Skip to main content

49 - References

References

Drug treatment of psychiatric symptoms in the context of other conditions CHAPTER 10 References

  1. Hely MA, et  al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23:837–844.
  2. Riedel O, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol 2010; 257:1073–1082.
  3. Reijnders JS, et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008; 23:183–189.
  4. Åström DO, et al. High risk of developing dementia in Parkinson’s disease: a Swedish registry-­based study. Sci Rep 2022; 12:16759.
  5. Wang W, et al. Bradyphrenia and tachyphrenia in idiopathic parkinsonism appear, in part, iatrogenic: an observational study with systematic review background. J Clin Med 2023; 12:6499.
  6. McDonald WM, et al. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol Psychiatry 2003; 54:363–375.
  7. Cong S, et al. Prevalence and clinical aspects of depression in Parkinson’s disease: a systematic review and meta‑analysis of 129 studies. Neurosci Biobehav Rev 2022; 141:104749.
  8. Rabinak CA, et al. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67:58–63.
  9. Rocha FL, et  al. Antidepressants for depression in Parkinson’s disease: systematic review and meta-­analysis. J Psychopharmacol 2013; 27:417–423.
  10. Liu J, et al. Comparative efficacy and acceptability of antidepressants in Parkinson’s disease: a network meta-­analysis. PLoS One 2013; 8:e76651.
  11. Troeung L, et  al. A meta-­analysis of randomised placebo-­controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One 2013; 8:e79510.
  12. Gony M, et al. Risk of serious extrapyramidal symptoms in patients with Parkinson’s disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26:142–145.
  13. Kulisevsky J, et  al. Motor changes during sertraline treatment in depressed patients with Parkinson’s disease. Eur J Neurol 2008; 15:953–959.
  14. Agüera-­Ortiz L, et al. Focus on depression in Parkinson’s disease: a Delphi consensus of experts in psychiatry, neurology, and geriatrics. Parkinsons Dis 2021; 2021:6621991.
  15. Richard IH, et  al. A randomized, double-­blind, placebo-­controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78:1229–1236.
  16. Bonuccelli U, et al. A non-­comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson’s disease. Expert Opin Pharmacother 2012; 13:2269–2280.
  17. Wang XL, et al. Comparative efficacy and acceptability of drug treatments for Parkinson’s disease with depression: a systematic review with network meta-­analysis. Eur J Pharmacol 2022; 927:175070.
  18. Avila A, et al. Agomelatine for depression in Parkinson disease: additional effect on sleep and motor dysfunction. J Clin Psychopharmacol 2015; 35:719–723.
  19. De Berardis D, et  al. Agomelatine treatment of major depressive disorder in Parkinson’s disease: a case series. J Neuropsychiatry Clin Neurosci 2013; 25:343–345.
  20. Vismara M, et al. Clinical uses of bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review. BMC Neurol 2022; 22:169.
  21. Santos García D, et al. Vortioxetine improves depressive symptoms and cognition in Parkinson’s disease patients with major depression: an open-­label prospective study. Brain Sci 2022; 12:1466.
  22. Barone P, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-­group randomized study. J Neurol 2006; 253:601–607.
  23. Antonini A, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol 2009; 8:929–937.
  24. Weintraub D, et  al. Impulse control disorders in Parkinson disease: a cross-­sectional study of 3090 patients. Arch Neurol 2010; 67:589–595.
  25. Li CT, et al. Pramipexole-­induced psychosis in Parkinson’s disease. Psychiatry Clin Neurosci 2008; 62:245.
  26. Ziaei E, et al. Comparison of pramipexole and citalopram in the treatment of depression in Parkinson’s disease: a randomized parallel-­group trial. J Res Med Sci 2022; 27:55.
  27. Figiel GS, et al. ECT-­induced delirium in depressed patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1991; 3:405–411.
  28. Friedman JH. Parkinson’s disease psychosis 2010: a review article. Parkinsonism Relat Disord 2010; 16:553–560.
  29. Ismail MS, et  al. A reality test: How well do we understand psychosis in Parkinson’s disease? J Neuropsychiatry Clin Neurosci 2004; 16:8–18.
  30. Kiziltan G, et al. Relationship between age and subtypes of psychotic symptoms in Parkinson’s disease. J Neurol 2007; 254:448–452.
  31. Factor SA, et al. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 2003; 60:1756–1761.
  32. Reich SG, et al. Ten most commonly asked questions about the psychiatric aspects of Parkinson’s disease. Neurologist 2003; 9:50–56.
  33. Lin JJ, et al. Genetic polymorphism of the angiotensin converting enzyme and L-­dopa-­induced adverse effects in Parkinson’s disease. J Neurol Sci 2007; 252:130–134.
  34. Stowe RL, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2008; 2:CD006564.
  35. Yunusa I, et al. Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson’s disease psychosis: systematic review and network meta-­analysis. J Geriatr Psychiatry Neurol 2023; 36:417–432.
  36. Divac N, et al. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson’s disease. Behav Neurol 2016; 2016:4938154.

844 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 10 37. Prohorov T, et al. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-­labeled study utilizing a structured interview. J Neurol 2006; 253:171–175. 38. Weintraub D, et  al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 2016; 73:535–541. 39. D’Angremont E, et al. Cholinesterase inhibitors for treatment of psychotic symptoms in Alzheimer disease and Parkinson disease: a meta-­ analysis. JAMA Neurol 2023; 180:813–823. 40. Chung KA, et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75:1263–1269. 41. Sawada H, et al. Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years. J Neurol Neurosurg Psychiatry 2018; 89:1332–1340. 42. Van Mierlo TJM, et al. Rivastigmine for minor visual hallucinations in Parkinson’s disease: a randomized controlled trial with 24 months follow-­up. Brain Behav 2021; 11:e2257. 43. Friedman JH. Clozapine is severely underused in Parkinson’s disease patients. Mov Disord Clin Pract 2022; 9:1021–1024. 44. Friedman JH, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology 1997; 48:1077–1081. 45. Pirttilä A, et al. Hospitalization and the risk of initiation of antipsychotics in persons with Parkinson’s disease. J Am Med Dir Assoc 2023; 24:1290–1296.e4. 46. Pintor L, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 2012; 35:61–66. 47. Mesquita J, et al. Fatal neuroleptic malignant syndrome induced by clozapine in Parkinson’s psychosis. J Neuropsychiatry Clin Neurosci 2014; 26:E34. 48. Ziegenbein M, et al. Clozapine-­induced aplastic anemia in a patient with Parkinson’s disease. Can J Psychiatry 2003; 48:352. 49. Iketani R, et al. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson’s disease: a systematic review and Bayesian network meta-­analysis. Parkinsonism Relat Disord 2020; 78:82–90. 50. Factor SA, et al. Combined clozapine and electroconvulsive therapy for the treatment of drug-­induced psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1995; 7:304–307. 51. Martin BA. ECT for Parkinson’s? CMAJ 2003; 168:1391–1392. 52. Sarva H, et al. Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis. Ther Adv Neurol Disord 2016; 9:462–473. 53. Rissardo JP, et al. Pimavanserin and Parkinson’s disease psychosis: a narrative review. Brain Sci 2022; 12:1286. 54. Alipour-­Haris G, et al. Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among medicare beneficiaries with Parkinson’s disease psychosis. Mov Disord Clin Pract 2023; 10:406–414. 55. Mansuri Z, et al. Pimavanserin in the treatment of Parkinson’s disease psychosis: meta-­analysis and meta-­regression of randomized clinical trials. Innov Clin Neurosci 2022; 19:46–51. 56. Wilby KJ, et al. Evidence-­based review of pharmacotherapy used for Parkinson’s disease psychosis. Ann Pharmacother 2017; 51:682–695. 57. Thames BH, et al. Clozapine: efficacy for Parkinson disease psychosis in patients refractory to pimavanserin. Parkinsonism Relat Disord 2023; 109:105356. 58. Richard IH, et al. Rivastigmine-­induced worsening of motor function and mood in a patient with Parkinson’s disease. Mov Disord 2001; 16 Suppl 1:33–34. 59. McKeith I, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-­blind, placebo-­controlled international study. Lancet 2000; 356:2031–2036. 60. Emre M, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351:2509–2518. 61. Aarsland D, et al. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72:708–712. 62. Pagano G, et al. Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-­analysis. J Neurol Neurosurg Psychiatry 2015; 86:767–773. 63. Rolinski M, et  al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012; 3:CD006504. 64. Dubois B, et  al. Donepezil in Parkinson’s disease dementia: a randomized, double-­blind efficacy and safety study. Mov Disord 2012; 27:1230–1238. 65. Connolly BS, et al. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311:1670–1683. 66. Emre M, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-­blind, placebo-­controlled trial. Lancet Neurol 2010; 9:969–977. 67. Seppi K, et  al. The Movement Disorder Society evidence-­based medicine review update: treatments for the non-­motor symptoms of Parkinson’s disease. Mov Disord 2011; 26 Suppl 3:S42–S80. 68. Nawaz H, et al. Anticholinergic medication burden in Parkinson’s disease outpatients. J Parkinsons Dis 2022; 12:599–606. 69. Mur J, et al. Association between anticholinergic burden and dementia in UK Biobank. Alzheimers Dement (NY) 2022; 8: e12290. 70. Zesiewicz TA, et al. Potential influences of complementary therapy on motor and non-­motor complications in Parkinson’s disease. CNS Drugs 2009; 23:817–835. 71. Biswas S, et  al. Study of the effects of nicotine and caffeine for the treatment of Parkinson’s disease. Appl Biochem Biotechnol 2023; 195:639–654. 72. Postuma RB, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012; 79:651–658.

No comments to display

Back to top